LF 15-0195 prevents from the development and inhibits the progression of rat experimental autoimmune myasthenia gravis.

Abstract

Experimental autoimmune myasthenia gravis (EAMG) is a T cell-dependent antibody-mediated neuromuscular autoimmune disease induced in susceptible rats by a single immunisation with torpedo acetylcholine receptor (AChR). Here, we report that subcutaneous administration of a novel immunosuppressant, LF 15-0195, is effective in inhibiting the induction and the progression of rat EAMG-suggesting that this drug may be used for preventive and curative treatment. The beneficial effect of LF 15-0195 is accompanied by decreased production of pathogenic autoantibodies and inhibition of the differentiation of antigen specific T cells into effector lymphocytes. These finding suggest that LF 15-0195 is a promising therapeutic for this autoimmune disease.

• Authors: Valérie Duplan, Patrick Dutartre, Philippe Druet, Abdelhadi Saoudi
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 129 Issue 1-2 Pg. 115-24 (Aug 2002) ISSN: 0165-5728 [Print] Netherlands
• PMID: 12161027 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Autoantibodies
• Guanidines
• Immunoglobulin G
• Immunosuppressive Agents
• Interleukins
• LF 150195
• Receptors, Cholinergic

Topics

• Animals
• Autoantibodies (drug effects, immunology)
• B-Lymphocytes (drug effects, immunology)
• Cell Differentiation (drug effects, immunology)
• Cell Division (drug effects, immunology)
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Guanidines (pharmacology)
• Immunoglobulin G (drug effects, immunology)
• Immunosuppressive Agents (pharmacology)
• Interleukins (biosynthesis, immunology)
• Lymphocyte Activation (drug effects, immunology)
• Male
• Myasthenia Gravis, Autoimmune, Experimental (drug therapy, immunology, physiopathology)
• Rats
• Rats, Inbred Lew
• Receptors, Cholinergic (immunology)
• T-Lymphocytes (drug effects, immunology)